Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 217 Show results per page	View Search Criteria \| Help With Results


1.		Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Other				HFHS 05-03 NCT00448240

Last Modified: 10/8/2008 First Published: 10/25/2004


2.		Phase III Randomized Study of Whole Brain Radiotherapy and Stereotactic Radiosurgery With Versus Without Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and Brain Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				RTOG-0320 RTOG-0320, NCT00096265


3.		Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				D-0410 NCT00153803

Last Modified: 12/20/2006 First Published: 12/9/2005


4.		Phase III Randomized Study of Combination Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil (Modified FOLFOX) or Oxaliplatin and Capecitabine (XELOX) in Combination With Bevacizumab With Versus Without Erlotinib in Patients With Unresectable Metastatic Colorectal Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 80				Other, Pharmaceutical / Industry				GERCOR-C04-2 EU-20565, GERCOR-OPTIMOX3-TARCEVA, ROCHE-GERCOR-C04-2, NCT00265824, GERCOR-DREAM- C04-2

Last Modified: 7/8/2008 First Published: 12/22/2005


5.		Phase III Randomized Study of Erlotinib in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Unsuitable for First-Line Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Over 18				Other				LLCG-TOPICAL EU-2004-000729-31, ISRCTN77383050, NCT00275132


6.		Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				TASMC-05-FB-05235-CTIL NCT00268684


7.		Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				75 to 90				Other				IFCT-0501 NCT00298415


8.		IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				Other				2005.386 NCT00300586


9.		TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over; 18 to 70 in Italy				Other				TORCH EUDRACT number: 2005-005968-90, NCT00349219


10.		RADIANT: A Study of Tarceva After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) - Positive Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				OSI-774-302 NCT00373425

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute